J&J’s TAR-200 Misses On Aim To Disrupt Muscle-Invasive Bladder Cancer

 
• By Jessica Merrill

A US regulatory filing for the drug/device combination product in earlier stages of bladder cancer remains on track for early 2025.

missed arrow
A Phase III trial testing TAR-200 missed on efficacy • Source: Shutterstock

More from Anticancer

More from Therapy Areas